Navigation Links
KaloBios Provides Update on KB001-A Partnership and Clinical Status
Date:7/28/2014

ctable="on">Pseudomonas aeruginosa (Pa) infection. KaloBios is conducting a 180 patient Phase 2 study in cystic fibrosis (CF) subjects with chronic Pa lung infection. KaloBios has received Orphan Drug designation from both the U.S. FDA and the European Medicines Agency for KB001-A for the treatment of Pa lung infection in CF patients. KB001-A has also received Fast Track Status from the U.S. FDA for the prevention of ventilator associated pneumonia. KaloBios is planning to seek a partner to help accelerate the development of this program.
  • KB004 is an anti-EphA3 mAb with potential in treating hematologic malignancies and solid tumors. KaloBios is running an ongoing Phase 1/2 study evaluating KB004 in hematologic malignancies. The Phase 1 dose escalation portion of that study in subjects with hematologic malignancies is ongoing. KaloBios initiated the Phase 2 expansion portion of the study focused on patients with certain EphA3 positive hematologic malignancies in early 2014.
  • KB003 is an anti-GM-CSF mAb with potential to treat inflammatory diseases that was being developed for the treatment of severe asthma. In early 2014, KaloBios completed a Phase 2 clinical study in 160 patients with severe asthma which did not meet its primary endpoint of improvement in FEV1 from baseline as compared to placebo. As a result, KaloBios discontinued development of this compound in severe asthma, and is continuing to analyze the Phase 2 data to review with thought leaders. KaloBios is currently evaluating other possible indications in order to determine next steps, if any, in the development of KB003.
  • All of the company's antibodies were generated using its proprietary Humaneered® technology, a method that converts nonhuman antibodies (typically mouse) into recombinant antibodies that have a high binding affinity to their target a
    '/>"/>

    SOURCE KaloBios Pharmaceuticals, Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. KaloBios Pharmaceuticals Announces Pricing of Initial Public Offering
    2. KaloBios Pharmaceuticals Completes Initial Public Offering
    3. KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma Data from KB002 Phase 1/2 Study Presented at the American Academy of Allergy, Asthma and Immunology Meeting
    4. KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma
    5. Bioassociate Announces Initiation of Coverage on KaloBios Pharmaceuticals, Inc.
    6. KaloBios to Present at Future Leaders in the Biotech Industry Conference
    7. KaloBios Targeted Antibacterial KB001-A to be Featured in BIO 2013 Panel Discussion of "New Defenses Against Old Enemies"
    8. KaloBios to Present at Needham Healthcare Conference
    9. KaloBios Reports First Quarter 2013 Financial Results
    10. KaloBios to Present at Stifel Healthcare Conference 2013
    11. KaloBios KB001 Anti-Pseudomonas Antibody Study Published in Pediatric Pulmonology
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/28/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/rktnl9/investigation ... "Investigation Report on China,s Insulin Aspart Market, 2010-2019" ... by Novo Nordisk, insulin aspart (under the trade ... the treatment of diabetes. Compared with human insulin, ... starts working fast and reports higher peak of ...
    (Date:8/28/2015)... Research and Markets ( http://www.researchandmarkets.com/research/sqh7xc/investigation ) ... on China,s Ranibizumab Market, 2012-2019" report to their ... by CFDA to treat wet age- related macular degeneration ... Novartis, is available in the Chinese market. However, in ... the treatment of wet AMD in China ...
    (Date:8/28/2015)... Shakti, LLC, today announced that it has changed its name ... Logo - http://photos.prnewswire.com/prnh/20150827/261551LOGO ... our transformation into a company focused on patent claim analysis ... validity." In ... the Company commenced a corporate re-branding initiative in order to ...
    Breaking Medicine Technology:China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2Investigation Report on China's Ranibizumab Market, 2012-2019 2IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2
    ... Endoscopy, Inc.,s (OTCPK: SNDY) is pleased to announce that ... of $73,895.  Solos Endoscopy has consummated agreements which resulted ... Three Months period ending September 30, 2011.  The signed ... reduction of ongoing expenses by approximately $40,000 per quarter. ...
    ... Health Company (FHCO- NASDAQ-CM) today announced that its exclusive distributor ... (PTY) Ltd., has received an order from the RSA Department ... for delivery as soon as possible. Shipments against the order ... Parrish, Chairman and C.E.O. of The Female Health Company, noted ...
    Cached Medicine Technology:Solos Endoscopy Finishes the 3rd Quarter With a Net Profit 2The Female Health Company's Distributor, Sekunjalo Investments Corporation (PTY) Ltd., Receives Order for 5 Million FC2 Female Condoms From the Republic of South Africa Department of Health 2The Female Health Company's Distributor, Sekunjalo Investments Corporation (PTY) Ltd., Receives Order for 5 Million FC2 Female Condoms From the Republic of South Africa Department of Health 3
    (Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... Dr. Tim ... mission. His mission is to increase acceptance of the chiropractic field in the ... that further debilitate them. Although Chiropractic was made available to the VA program ...
    (Date:8/29/2015)... ... August 29, 2015 , ... People who have ... (including emphysema), or asthma, are at higher risk from wildfire smoke especially in ... failure or heart-rhythm problems (arrhythmia or irregular heartbeat) are also sensitive to air ...
    (Date:8/28/2015)... ... August 29, 2015 , ... Rio Salado College joined ... student experience as part of the EDUCAUSE - Next Generation Learning Challenges 2015 Breakthrough ... is the third Breakthrough Models Incubator hosted by EDUCAUSE and NGLC, which ...
    (Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... The Kentucky ... workers are qualified for the position they are applying for, they are unable to ... many employers are considering altering drug testing policies in order to be able to ...
    (Date:8/28/2015)... ... August 28, 2015 , ... ... FDA’s Position and Best Practices for Compliance, **Presented by FDAnews and GessNet**, ... chaired by internationally renowned expert Fubin Wu, has been specifically designed to ...
    Breaking Medicine News(10 mins):Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 2Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 3Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 4Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 5
    ... treated at Presbyterian Hospital of Dallas for anorexia and ... and doctors there took part in a fraudulent billing ... ,According to the complaint filed today in ... in Presbyterian's Eating Disorder Program. There, psychiatrist Dr. Urszula ...
    ... Research and Manufacturers of America (PhRMA) finds that biopharmaceutical ... three leading causes of death of Americans -- ... clinical trials or under review by the Food and ... are still leading causes of death in the United ...
    ... to lose muscle mass and grow frail? One important factor ... elderly to respond to the muscle-building stimulus of the ... link to diabetes a condition in which either a ... activity (as in type 2 diabetes) causes blood sugar levels ...
    ... agreement with Mitsubishi Pharma Corporation, a subsidiary of ... expect to generate and evaluate fully human monoclonal ... treatment of autoimmune diseases. The companies plan to ... generate antibodies for research and possible development. ...
    ... study shows that combination therapies - combining two ... to be viable, affordable options for pharmaceutical brand ... value. ,Cutting Edge Information's report "Pharmaceutical Product ... New Market Entry Strategies" reveals that 58% of ...
    ... unabated across the Atlantic. But the man who set off ... Denver that specializes in the disease. The man himself ... Atlanta. He is not coughing, has no fever and does ... said. ,Still, staff at the National Jewish Medical ...
    Cached Medicine News:Health News:Anorexia Patients Sue Dallas' Presbyterian Hospital 2Health News:More Than 270 Medicines in Testing for Heart Disease and Stroke 2Health News:Aerobic Exercise Helps Maintain Muscle in Elderly: Research 2Health News:Combination Therapies Continue to Thrive Among Pharma Brands 2Health News:American Who Set Off TB Scare Doing Well in Hospital 2Health News:American Who Set Off TB Scare Doing Well in Hospital 3
    ... III DLE (Drug List Editor) Multi-Channel Infusion ... infusion technology. The instrument combines three independent ... versatility in an unparalleled small size. Now ... III Infusion System simplifies the delivery of ...
    ... The Gemini Family of infusion ... with a collective series of ... product line offers a wide ... IV sets, each featuring the ...
    ... first steps any hospital or health system ... powerful, most effective tools available for physicians ... clinician documentation and electronic medical record (EMR) ... this goal. In fact, its the most ...
    ... specialty Eraser instruments have been designed ... the right tool for situations requiring ... series of 25 gauge intraocular, bipolar, ... treatment of target tissues for fine-tip ...
    Medicine Products: